BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2201 related articles for article (PubMed ID: 26361971)

  • 1. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
    Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
    Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
    Takashima A; García-Alfonso P; Manneh R; Beşen AA; Hong YS; Cuyle PJ; Yanez P; Burge M; Yoshino T; Kim TW; Cui K; Li C; Jain R; Adelberg D; Taieb J
    Eur J Cancer; 2024 Jul; 205():114036. PubMed ID: 38749110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in
    Modest DP; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; Fischer von Weikersthal L; Caca K; Kretzschmar A; Goekkurt E; Haas S; Kurreck A; Stahler A; Held S; Jarosch A; Horst D; Reinacher-Schick A; Kasper S; Heinemann V; Stintzing S; Trarbach T
    J Clin Oncol; 2022 Jan; 40(1):72-82. PubMed ID: 34533973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A
    Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 111.